COST-EFFECTIVENESS OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FOR THE TREATMENT OF HIV-1 IN TAIWAN

被引：0
|
作者：
Wen, Y. C. [1 ]
Ou, H. T. [2 ]
Tien, K. [1 ]
Harrison, C. [3 ]
Omonmhenle, D. [3 ]
Turner, M. [3 ]
Anderson, S. J. [4 ]
Jacob, I [5 ]
机构：
[1] GSK, Taipei, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan, Taiwan
[3] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[4] GlaxoSmithKline, Brentford, England
[5] ViiV Healthcare, Brentford, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE473
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [1] Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
    Swindells, Susan
    Andrade-Villanueva, Jaime-Federico
    Richmond, Gary J.
    Rizzardini, Giuliano
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Pokrovsky, Vadim
    Bredeek, Fritz
    Smith, Graham
    Cahn, Pedro
    Kim, Yeon-Sook
    Ford, Susan L.
    Talarico, Christine L.
    Patel, Parul
    Chounta, Vasiliki
    Crauwels, Herta
    Parys, Wim
    Vanveggel, Simon
    Mrus, Joseph
    Huang, Jenny
    Harrington, Conn M.
    Hudson, Krischan J.
    Margolis, David A.
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1112 - 1123
  • [2] Cabotegravir long-acting for HIV-1 prevention
    Andrews, Chasity D.
    Heneine, Walid
    [J]. CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 258 - 263
  • [3] Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study
    Parker, Ben
    Ward, Tom
    Hayward, Olivia
    Jacob, Ian
    Arthurs, Erin
    Becker, Debbie
    Anderson, Sarah-Jane
    Chounta, Vasiliki
    Van de Velde, Nicolas
    [J]. PLOS ONE, 2021, 16 (02):
  • [4] COST-EFFECTIVENESS OF CABOTEGRAVIR (CAB) plus RILPIVIRINE (RPV) LONG-ACTING (LA) IN PEOPLE LIVING WITH HIV (PLHIV) IN AUSTRIA
    Uhl, G.
    Schroeder, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S125 - S125
  • [5] Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
    Orkin, Chloe O. C.
    Arasteh, Keikawus A. K.
    Hernandez-Mora, M. Gorgolas M. G. H. M.
    Pokrovsky, Vadim P. V.
    Overton, Edgar T. O. E. T.
    Girard, Pierre-Marie G. P. M.
    Oka, Shinichi O. S.
    Walmsley, Sharon W. S.
    Bettacchi, Chris B. C.
    Brinson, Cynthia B. C.
    Philibert, Patrick P. P.
    Lombaard, Johan L. J.
    Clair, Marty C. M.
    Crauwels, Herta C. H.
    Ford, Susan L. F. S. L.
    Patel, Parul P. P.
    Chounta, Vasiliki C. V.
    D'Amico, Ronald D. R.
    Vanveggel, Simon V. S.
    Dorey, David D. D.
    Cutrell, Amy C. A.
    Griffith, Sandy G. S.
    Margolis, David A. M. D. A.
    Williams, Peter E. W. P. E.
    Parys, Wim P. W.
    Smith, Kimberly Y. S. K. Y.
    Spreen, William R. S. W. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1124 - 1135
  • [6] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
    Orkin, C.
    Oka, S.
    Philibert, P.
    Brinson, C.
    Bassa, A. C.
    Gusev, D.
    Degen, O.
    Gonzalez Garcia, J.
    D'Amico, R.
    Dorey, D.
    Griffith, S.
    Margolis, D. A.
    St Clair, M.
    Williams, P.
    Spreen, W. R.
    [J]. HIV MEDICINE, 2020, 21 : 14 - 14
  • [7] Cost-utility analysis of long-acting cabotegravir plus rilpivirine for the treatment of HIV infection in the United Kingdom
    Parker, B.
    Chounta, V.
    Gait, C.
    Hayward, O.
    Hunjan, M.
    Schroeder, M.
    Jacob, I.
    Van de Velde, N.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 37 - 37
  • [8] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results
    Swindells, S.
    Lutz, T.
    Van Zyl, L.
    Porteiro, N.
    Benn, P.
    Huang, J.
    Harrington, C.
    Hove, K.
    Ford, S.
    Talarico, C.
    Chounta, V.
    Crauwels, H.
    Van Solingen-Ristea, R.
    Vanveggel, S.
    Margolis, D.
    Smith, K.
    Vandermeulen, K.
    Spreen, W.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 19 - 21
  • [9] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS week 96 results
    Swindells, Susan
    Lutz, Thomas
    Van Zyl, Lelanie
    Porteiro, Norma
    Benn, Paul
    Huang, Jenny O.
    Harrington, Conn M.
    Hove, Kai
    Ford, Susan L.
    Talarico, Christine L.
    Chounta, Vasiliki
    Crauwels, Herta
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Margolis, David A.
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Spreen, William R.
    Baum, Alexander
    [J]. INFECTION, 2021, 49 (SUPPL 1) : S7 - S8
  • [10] An evaluation of long-acting cabotegravir plus rilpivirine for the treatment of virologically suppressed adults living with HIV
    Qazzaz, Hamdi
    Parganas, Christopher
    Cory, Theodore James
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1485 - 1495
12345